Marino Garcia, Dianthus CEO

5AM, Avid­i­ty, Fi­deli­ty lead $100M in­fu­sion in­to next-gen, tar­get­ed com­ple­ment ap­proach

When the FDA first ap­proved Alex­ion’s Soliris — then eculizum­ab — in 2007, ex­perts cel­e­brat­ed how the first-of-its-kind drug trans­formed the way physi­cians could treat a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.